Magic mushrooms ‘could treat depression’

The move to investigate psilocybin as a possible treatment for serious
depression is linked to results from two far-reaching scientific studies.

In one, volunteers were given psilocybin infusions while undergoing functional
magnetic resonance imaging (fMRI) brain scans.

The findings, reported today in the journal Proceedings of the National
Academy of Sciences, showed the drug disconnected two key ”hub” regions of
the brain with multiple connections to other areas.

One of these regions, the medial prefrontal cortex (mPFC) is known to be
hyperactive in people with depression. The other, the posterior cingulate
cortex (PCC) at the back of the brain, is thought to play a role in
consciousness and self-identity.

The second study, soon to be published in the British Journal of Psychiatry,
found that the magic mushrooms chemical enhanced memories associated with
positive emotions.

Scans showed that the memory experience was very ”real”. Activity was
increased in brain regions that processed vision and other sensory
information.

Speaking to journalists in London, Prof Nutt said the findings were ”a
revelation”.

”Psychedelics are thought of as ‘mind-expanding’ drugs so it has commonly
been assumed that they work by increasing brain activity, but surprisingly,
we found that psilocybin actually caused activity to decrease in areas that
have the densest connections with other areas.

”These hubs constrain our experience of the world and keep it orderly. We now
know that deactivating these regions leads to a state in which the world is
experienced as strange.”

It is the first time serious research has been carried out on the effects of
”psychedelic” drugs for more than 50 years.

In the 1950s and 1960s, scientists investigating drugs such as LSD and
psilocybin carried out studies on around 40,000 patients and published 1,000
papers.

Such work was brought to an abrupt halt when the drugs came to be seen as
social evils and were made illegal.

”They got banned because they could be society changing,” said Prof Nutt.
”There was great concern about that. Since then they’ve been virtually
impossible to research.”

He said finding support for the new studies had been ”damned difficult”.
Neither the Medical Research Council (MRC) nor the Wellcome Trust, Britain’s
biggest research charity, had been willing to fund them. And both Nature and
Science, the two most prestigious scientific journals, refused to publish
the findings.

Now the MRC is said to be showing interest in the planned clinical trial,
which Prof Nutt believes could be undertaken this year with sufficient
backing.

Twenty six patients with a history of serious depression which cannot be
treated with drugs or cognitive behavioural therapy (CBT) are expected to
take part.

Half will be treated with psilocybin while trained psychotherapists prompt
them to recollect happy memories and think positively.

Findings from the earlier research suggest the positive effects of the drug
might be long-lasting, or even permanent.

After the treatment, the patients’ progress will be monitored for a year.
Their responses will be compared with those of a ”placebo group” of
another 13 patients given infusions of a salt solution containing no
psilocybin.

For safety reasons, both the PNAS and British Journal of Psychiatry studies
involved healthy volunteers unaffected by mental problems. All had also
taken hallucinogenic drugs in the past without reacting badly to them.

Thirty participants took part in the PNAS study and ten in the British Journal
of Psychiatry study.

Volunteers had a range of vivid and ”dreamlike” experiences including seeing
geometric patterns, an altered sense of time, and the ”Alice in
Wonderland” sensation of being either very big or very small.

They also underwent ”mystical” transformations of the sort reported by
Buddhist monks who practise deep meditation. This has been described as the
”ego dissolving” and becoming ”one with the universe”.

One volunteer described the effect of psilocybin as being like ”kneeling
before God”.

Prof Nutt stressed that people should not be tempted to conduct their own
experiments with magic mushrooms.

”This is a research tool which may give us insights into how to treat
depression,” he said. ”I would strongly resist people self-medicating.”

Dr Kevin Healy, who chairs the Royal College of Psychiatrists’ Faculty of
Medical Psychotherapy, described the British Journal of Psychiatry study as
”interesting” but added: ”We are clearly nowhere near seeing psilocybin
used regularly and widely in psychotherapy practice.

”Although this study found that psilocybin enhanced autobiographical
recollection in 10 healthy volunteers, we have no evidence that it would
enhance a therapeutic response in patients, where the experienced
relationship between patient and therapist is central to the therapeutic
work.”

Recipes for Mushrooms with Bill & Sheila
_____________________________________________________________________
If you require a high quality printout of this article, just click on the printer symbol next to ’Share and enjoy’, and we will do the rest. This site is hosted by (click on the graphic for more information)

Return from mushrooms to Home Page

If you want to increase your site popularity and gain thousands of visitors – check out these sites THEY ARE FREE. Spanishchef more than doubled its ‘New Visitors’ last month simply by signing up to these sites:




Follow spanishchef.net on TWITTER